JO3568B1 - عوامل ربط cd123 واستخداماتها - Google Patents

عوامل ربط cd123 واستخداماتها

Info

Publication number
JO3568B1
JO3568B1 JOP/2015/0216A JOP20150216A JO3568B1 JO 3568 B1 JO3568 B1 JO 3568B1 JO P20150216 A JOP20150216 A JO P20150216A JO 3568 B1 JO3568 B1 JO 3568B1
Authority
JO
Jordan
Prior art keywords
span
dir
rtl
antibodies
ltr
Prior art date
Application number
JOP/2015/0216A
Other languages
English (en)
Inventor
Wheeler John
Gaudet Francois
Luo Jinquan
Li Yingzhe
H Tam Susan
M Attar Ricardo
Teplyakov Alexey
Wu Sheng-Jiun
F Nemeth Jennifer
Mcdaid Ronan
C Harman Benjamin
C Pomerantz Steven
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3568B1 publication Critical patent/JO3568B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

بولي نوكليوتيد تخليقي معزول يشفر الجسم المضاد ثنائي النوعية<span dir="LTR"> HC1</span>، <span dir="LTR">HC2</span>، يشتمل<span dir="LTR"> LC1 </span>أو<span dir="LTR"> HC2 </span>من<span dir="LTR"> CD123 (IL3-Rα) x CD3 </span>أو شظية رابطة ثنائية النوعية وفقًا لأي من عناصر الحماية 31 إلى 66<span dir="LTR">.</span> <span dir="RTL">تم بهذه الوثيقة توفير أجسام مضادة ترتبط على نحو محدد للمناعة بـ </span>CD123<span dir="RTL">. يتعلق الاختراع الحالي ببولي نوكليوتيدات يمكنها تشفير الأجسام المضادة التي تم توفيرها والتي لها نوعية تجاه </span>CD123<span dir="RTL"> أو الشظايا الرابطة لمولِّدت الضد، خلايا تعبر عن الأجسام المضادة التي تم توفيرها أو شظايا رابطة لمولِّدت ضد، وكذلك النواقل المرتبطة وأجسام مضادة مرقَّمة بصورة قابلة للكشف أو شظايا رابطة لمولِّدت ضد. إضافةً إلى ذلك، طرق لاستخدام الأجسام المضادة التي تم توفيرها تم وصفها. على سبيل المثال، يمكن استخدام الأجسام المضادة التي تم توفيرها لتشخيص، أو علاج، أو مراقبة تقدم سرطان يعبر وراثيًا عن </span>CD123<span dir="RTL">، أو تراجعه، أوثباته؛ لتحديد ما إذا كان ينبغي معالجة مريض من السرطان أم لا؛ أو لتحديد ما إذا كان الخاضع مصابًا بسرطان يعبر وراثيًا عن </span>CD123<span dir="RTL"> أم لا وبالتالي يستجيب للعلاج بعلاج مضاد للسرطان له نوعية تجاه </span>CD123<span dir="RTL">، مثل الأجسام متعددة النوعية المضادة لـ </span>CD123<span dir="RTL"> و</span>CD3<span dir="RTL"> والتي ورد وصفها هنا.</span>
JOP/2015/0216A 2014-09-05 2015-09-03 عوامل ربط cd123 واستخداماتها JO3568B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462046682P 2014-09-05 2014-09-05

Publications (1)

Publication Number Publication Date
JO3568B1 true JO3568B1 (ar) 2020-07-05

Family

ID=54150667

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0216A JO3568B1 (ar) 2014-09-05 2015-09-03 عوامل ربط cd123 واستخداماتها

Country Status (39)

Country Link
US (1) US9850310B2 (ar)
EP (2) EP3722315A1 (ar)
JP (2) JP6805130B2 (ar)
KR (1) KR102540192B1 (ar)
CN (1) CN107074956B (ar)
AR (1) AR101765A1 (ar)
AU (1) AU2015311931B2 (ar)
CA (1) CA2959171C (ar)
CL (1) CL2017000515A1 (ar)
CO (1) CO2017002196A2 (ar)
CR (1) CR20170079A (ar)
CY (1) CY1122858T1 (ar)
DK (1) DK3189081T3 (ar)
EA (1) EA037647B1 (ar)
EC (1) ECSP17020812A (ar)
ES (1) ES2791249T3 (ar)
HR (1) HRP20200745T1 (ar)
HU (1) HUE048791T2 (ar)
IL (1) IL250770B (ar)
JO (1) JO3568B1 (ar)
LT (1) LT3189081T (ar)
MA (2) MA53145A (ar)
ME (1) ME03724B (ar)
MX (1) MX384424B (ar)
MY (1) MY186337A (ar)
NI (1) NI201700025A (ar)
PE (1) PE20171556A1 (ar)
PH (1) PH12017500472A1 (ar)
PL (1) PL3189081T3 (ar)
PT (1) PT3189081T (ar)
RS (1) RS60305B1 (ar)
SG (1) SG11201701599UA (ar)
SI (1) SI3189081T1 (ar)
SM (1) SMT202000253T1 (ar)
TW (1) TWI693233B (ar)
UA (1) UA120060C2 (ar)
UY (1) UY36289A (ar)
WO (1) WO2016036937A1 (ar)
ZA (1) ZA201702369B (ar)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
EP3812398A3 (en) 2015-01-23 2021-07-21 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
SMT202100092T1 (it) 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
AU2017267793B2 (en) * 2016-05-20 2024-01-25 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017211731A1 (en) 2016-06-06 2017-12-14 F. Hoffmann-La Roche Ag Fusion proteins for ophthalmology with increased eye retention
KR20190015520A (ko) 2016-06-07 2019-02-13 마크로제닉스, 인크. 조합 치료법
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
AU2017331256B2 (en) 2016-09-21 2024-11-07 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
JP7685735B2 (ja) 2016-12-02 2025-05-30 アンヘレス セラピューティクス インコーポレイテッド 合成免疫受容体およびその使用方法
CA3049689A1 (en) * 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for augmenting antibody mediated receptor signaling
JP7132232B2 (ja) 2017-02-24 2022-09-06 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
ES3014984T3 (en) * 2017-03-14 2025-04-28 Sunshine Lake Pharma Co Ltd Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
WO2019050521A1 (en) * 2017-09-07 2019-03-14 Macrogenics, Inc. DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
MX2020004381A (es) * 2017-10-27 2020-08-20 Pfizer Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos.
JP2021505637A (ja) 2017-12-12 2021-02-18 マクロジェニクス，インコーポレーテッド 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
CN120399075A (zh) * 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
SG11202011306TA (en) 2018-05-16 2020-12-30 Janssen Biotech Inc Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
MA52777A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Agents de liaison psma et utilisations correspondantes
CR20200564A (es) 2018-05-24 2021-06-21 Janssen Biotech Inc Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
US20220275081A1 (en) * 2018-10-17 2022-09-01 Good T Cells, Inc. Binding molecule specific for lrig-1 protein and use thereof
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
CN113874400B (zh) * 2019-03-11 2025-02-07 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
AU2020267504A1 (en) * 2019-05-08 2021-12-02 Janssen Biotech, Inc. Materials and methods for modulating T cell mediated immunity
KR20220008866A (ko) 2019-05-14 2022-01-21 하푼 테라퓨틱스, 인크. EpCAM 결합 단백질 및 사용 방법
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
CN113912694B (zh) * 2019-07-24 2023-05-30 暨南大学 靶向cd133的结合蛋白和应用
GB201912681D0 (en) 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
KR20230051617A (ko) 2020-03-13 2023-04-18 얀센 바이오테크 인코포레이티드 Siglec-3/cd33을 결합시키기 위한 물질 및 방법
CN115666727A (zh) * 2020-05-19 2023-01-31 詹森生物科技公司 包含t细胞重定向治疗剂和vla-4粘附途径抑制剂的组合物
EP4153314A4 (en) 2020-05-19 2024-05-22 The Regents of The University of California POLYPEPTIDES AND CONJUGATE VACCINES FOR INDUCING IMMUNE RESPONSES
AU2021339754A1 (en) 2020-09-11 2023-05-25 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
US12024559B2 (en) * 2020-10-23 2024-07-02 Asher Biotherapeutics, Inc. Fusions with CD8 antigen binding molecules for modulating immune cell function
AU2021414400A1 (en) 2020-12-31 2023-08-17 Innate Pharma Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
RS66868B1 (sr) 2021-01-28 2025-06-30 Regeneron Pharma Kompozicije i postupci za lečenje sindroma oslobađanja citokina
CA3220458A1 (en) * 2021-05-18 2022-11-24 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
GB2638094B (en) 2021-05-19 2026-03-04 Asher Biotherapeutics Inc IL-21 Polypeptides And Targeted Constructs
WO2023019121A2 (en) * 2021-08-09 2023-02-16 Merck Patent Gmbh Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
WO2023138666A1 (en) * 2022-01-19 2023-07-27 Utc Therapeutics (Shanghai) Co., Ltd. Circular rna and use thereof
CA3247475A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR THE DESTRUCTION OF UNIVERSAL TUMOR CELLS
CN119365495A (zh) 2022-05-27 2025-01-24 赛诺菲 与NKp46和BCMA变体结合的具有Fc工程化的自然杀伤（NK）细胞接合物
JP2026506095A (ja) 2023-02-17 2026-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３／ｔａａ二重特異性抗体に応答する誘導ｎｋ細胞

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
EP1538206B1 (en) 1997-09-16 2010-03-24 Centocor, Inc. Method for the complete chemical synthesis and assembly of genes and genomes
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
JP5694923B2 (ja) * 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011038301A2 (en) * 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
ES2924722T3 (es) * 2012-05-18 2022-10-10 Aptevo Res & Development Llc Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3

Also Published As

Publication number Publication date
ME03724B (me) 2021-01-20
PT3189081T (pt) 2020-05-25
PE20171556A1 (es) 2017-10-27
MY186337A (en) 2021-07-13
UY36289A (es) 2016-04-01
WO2016036937A1 (en) 2016-03-10
JP2017529838A (ja) 2017-10-12
MA40609B1 (fr) 2020-05-29
CY1122858T1 (el) 2021-05-05
EP3722315A1 (en) 2020-10-14
CA2959171A1 (en) 2016-03-10
SI3189081T1 (sl) 2020-07-31
PH12017500472A1 (en) 2017-07-31
PL3189081T3 (pl) 2020-10-05
EP3189081B1 (en) 2020-02-19
BR112017004322A2 (pt) 2017-12-05
HRP20200745T1 (hr) 2020-08-07
EA037647B1 (ru) 2021-04-27
MA53145A (fr) 2021-05-19
ECSP17020812A (es) 2018-07-31
TWI693233B (zh) 2020-05-11
KR20170049554A (ko) 2017-05-10
TW201625687A (zh) 2016-07-16
CN107074956A (zh) 2017-08-18
AR101765A1 (es) 2017-01-11
ES2791249T3 (es) 2020-11-03
DK3189081T3 (da) 2020-05-04
CL2017000515A1 (es) 2018-03-16
MX384424B (es) 2025-03-14
LT3189081T (lt) 2020-05-11
NI201700025A (es) 2017-06-22
AU2015311931A1 (en) 2017-03-16
AU2015311931B2 (en) 2020-09-03
HUE048791T2 (hu) 2020-09-28
IL250770A0 (en) 2017-04-30
US9850310B2 (en) 2017-12-26
UA120060C2 (uk) 2019-09-25
SG11201701599UA (en) 2017-03-30
MX2017002891A (es) 2017-10-11
EP3189081A1 (en) 2017-07-12
US20160068605A1 (en) 2016-03-10
RS60305B1 (sr) 2020-07-31
CN107074956B (zh) 2021-11-26
IL250770B (en) 2020-10-29
EA201790530A1 (ru) 2018-03-30
KR102540192B1 (ko) 2023-06-02
JP2021050216A (ja) 2021-04-01
CR20170079A (es) 2017-04-27
JP6805130B2 (ja) 2020-12-23
CA2959171C (en) 2023-11-14
ZA201702369B (en) 2018-12-19
SMT202000253T1 (it) 2020-07-08
CO2017002196A2 (es) 2017-07-28

Similar Documents

Publication Publication Date Title
CL2019000146A1 (es) Anticuerpos anti - gprc5d, moléculas de unión de antigeno bioespecificos que enlazan gprc5d y cd3, y usos relacionados.
ZA201708265B (en) Tigit-binding agents and uses thereof
EA201790530A1 (ru) Агенты, связывающиеся с cd123, и виды их применения
PE20200012A1 (es) Anticuerpos mono- y biespecificos que se unen al factor de coagulacion ix y al factor de coagulacion x
MX2017013298A (es) Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b.
EA201791093A1 (ru) Антитела к cd47, способы и применение
JO3792B1 (ar) تركيبات الجسم المضاد لـ flt3 و cd3
EA201791485A1 (ru) Анти-cd47-антитела и их применения
PH12017501190B1 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
GEP20197034B (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
PH12017501166A1 (en) Antibodies to tight
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX2016014210A (es) Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.
MX2017005814A (es) Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion.
BR112018016697A2 (pt) anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento.
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
JO3800B1 (ar) الأجسام المضادة لمضادات &#34;اي ال1 ار ايه بيه&#34; وجزيئات ربط المستضدات ثنائية الاجسام المضادة التي تربط ما بين &#34;اي ال1 ار ايه بيه&#34; و &#34;سي دي 3&#34; والاستخدامات الخاصة بها
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
MX2017003247A (es) Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
JOP20200161B1 (ar) أجسام مضادة أحادية النسيلة وطرق استخدامها
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MA40536A (fr) Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения